Carregant...
A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy and improved outcomes for patients with advanced disease. Pembrolizumab, a monoclonal antibody that acts as a programmed cell death 1 (PD-1(PDCD1)) inhibitor, has been approved for the treatment of advanced melanoma and other sol...
Guardat en:
| Publicat a: | Endocrinol Diabetes Metab Case Rep |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bioscientifica Ltd
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6432978/ https://ncbi.nlm.nih.gov/pubmed/30836329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-18-0153 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|